Role of upper gastrointestinal investigations in a screening study for colorectal neoplasia

W M Thomas, J D Hardcastle

Abstract
Should patients with positive faecal occult blood screening tests who are free of colorectal neoplasia undergo upper gastrointestinal investigation? Altogether 16 985 faecal occult blood tests were completed in a group of 18 818 asymptomatic patients (45–75 years) offered screening at two yearly intervals. A total of 447 (2-6%) were positive and underwent large bowel investigations. No neoplastic disease was identified in 283 (63%) of them. Fourteen (5%) also underwent gastroscopy for upper gastrointestinal symptoms, benign conditions were identified in five and a gastric carcinoma in one. No further investigations were instituted in the remaining 269 subjects who have now been followed up for a median period of 5 years (2–8 years). Five have been referred for benign upper gastrointestinal conditions, but none for upper gastrointestinal malignancy. Thirty one subjects have died – one from gastric cancer (a patient who had undergone a previous partial gastrectomy for a duodenal ulcer and who had persistent upper gastrointestinal symptoms). The remaining deaths were unrelated to the upper gastrointestinal tract. Nineteen people who have left the trial area have been monitored for the development of malignant disease; none have presented with upper gastrointestinal malignancy. These data support the view that upper gastrointestinal investigations need not be performed routinely in this group of subjects, but may be reserved for those with relevant symptoms.

Most patients with colorectal carcinoma present at a stage when the disease has spread to regional lymph nodes or has metastasised to distant organs. This is considered to be a major factor in the overall poor prognosis after treatment. The aim of screening for large bowel cancer is to detect the disease in its presymptomatic phase, when it is likely to be less advanced and curative surgical resection is possible.

Early results from the randomised trials of faecal occult blood screening are encouraging. It has been established that asymptomatic colorectal cancer can be detected by simple tests for faecal occult blood; furthermore these cancers are generally at a less advanced pathological stage than those occurring in the control populations.

The test which has been most extensively studied, Haemoccult, has been shown to have a sensitivity for carcinoma of 45–74% and, considering a diagnosis of carcinoma or adenoma to be a true positive, a specificity of 98–99% in asymptomatic subjects. Feca EIA, a test which combines a chemical test of increased sensitivity for blood with a human-specific immunological test, has also been used in a cohort of patients in the Nottingham study. It has been shown to have a higher sensitivity for neoplasia but a correspondingly lower specificity, resulting in a higher rate of false positive reactions. While accepting that the specificity for neoplasia of both tests is high, when applied to the large numbers involved in mass population screening an appreciable number of people will be shown to be free of colorectal neoplasia after investigation of the large bowel. In most of these no satisfactory cause for the positive test will be apparent.

Healthy people may lose gastrointestinal blood in sufficient amounts to result in a positive faecal occult blood test; furthermore dietary factors may be responsible for false positive results. Nevertheless, failure to identify a colonic source of bleeding in subjects with positive faecal occult blood tests poses a question of great practical and ethical importance – should they undergo investigation of the remainder of the gastrointestinal tract to exclude pathology at sites other than the colorectum?

We have aimed to answer this question by reviewing the subjects in whom no colonic neoplasia was identified after investigation of positive faecal occult blood tests in a large randomised study of screening for colorectal neoplasia.

Given the high prevalence of diverticular disease and benign perianal conditions (in particular haemorrhoids) in this age group, we have not considered either of these diagnoses as a satisfactory explanation of a positive faecal occult blood test.

Method
Asymptomatic subjects between 50 and 74 years of age were identified from general practitioner lists. After stratification by age and sex they were randomly allocated to a test group who received faecal occult blood tests or to a control group who were not approached.

After completion, the tests were interpreted by experienced staff and those with positive tests were seen in a designated early diagnosis clinic. A full history, including upper gastrointestinal symptoms, was taken. Subjects subsequently underwent either colonoscopy or flexible sigmoidoscopy and double contrast barium enema.

Upper gastrointestinal investigations were not performed routinely, but subjects with relevant symptoms – for example, dyspepsia or dysphagia – were referred for gastroscopy.

Subjects with negative tests, or in whom colonic investigations were normal, were
We have considered the diagnosis of colorectal carcinoma or histologically proved adenoma to be a true positive faecal occult blood test. In addition, conditions known to produce colonic bleeding – for example, ulcerative colitis – have been recorded.

In general, Haemoccult was the screening test used, but some subjects were screened with Feca EIA.

Results
A total of 18,818 subjects were offered faecal occult blood tests and those who complied were offered future tests at two yearly intervals. Altogether 7,644 have been rescreened once and 3,541 rescreened twice, a total of 30,003 screening episodes (Fig 1). Overall 16,985 (56-6%) of tests were completed (8,123 (43-2%) at the initial screen, 5,976 (78-2%) at the first rescreen, and 2,886 (81-5%) at the second rescreen.

Some 15,572 subjects completed Haemoccult and 2,717 completed Feca EIA tests (1,304 completed both tests). A total of 292 (1-9%) of the Haemoccult tests were positive for faecal occult blood. Further investigation showed neoplastic disease in 137 (46-9%) subjects and no neoplastic disease in 155 (53-1%). The rate of positive reactions and yield of neoplasia of Feca EIA in comparison with Haemoccult has been reported previously. Of the 2,717 participants who completed Feca EIA tests, 154 (5-7%) were positive. Investigation of these showed neoplastic disease in 26 (16-9%) and no neoplastic disease in 128 (83-1%).

Overall, of the 446 subjects with positive tests, colorectal neoplasia was not identified in 283 (63-5%) (Fig 2). Fourteen (5%) of these also underwent gastroscopy for upper gastrointestinal symptoms, benign gastroduodenal disease being identified in five and an early gastric cancer in one. Four patients with chronic, intermittent dyspepsia were not investigated.

No further investigations were instituted in the remaining 269 subjects.

In seven of these patients there was endoscopic and histological evidence of ulcerative colitis or colonic Crohn’s disease, and of a radiation colitis (secondary to treatment of a carcinoma of the uterine cervix) in one. These were considered to be the cause of the positive faecal occult blood tests, leaving 261 subjects in whom no satisfactory cause for blood loss was identified. These have now been followed up for a median period of 5 (range 2–8) years.

During this time a diagnosis of benign upper gastrointestinal disease has been made in five subjects after the investigation of symptoms that have developed since the patients were screened.

Three patients who had negative double contrast barium enema examinations subsequently presented with large bowel carcinoma (affecting the caecum in all cases) in the interval between the examinations and a rescreen at two years; these are presumed to have been missed by barium enema examination.

A total of 31 subjects have died – one of gastric carcinoma (a patient who had undergone a previous partial gastrectomy for duodenal ulcer). The remaining deaths were unrelated to the
upper gastrointestinal tract, the principal causes of death being secondary to cardiovascular disease (11 patients) or respiratory disorders (seven patients).

Nineteen patients who have left the trial area have been monitored for the development of malignant disease, but none have presented with gastrointestinal malignancy.

Discussion

Total visualisation of the colorectal mucosa by radiological or endoscopic means is mandatory in screened subjects with positive faecal occult blood tests.

In the Nottingham study colonoscopy is currently the investigation of choice as it allows endoscopic resection of polypoidal lesions at the time of the examination. Double contrast barium enema is supplemented to complement colonoscopy in those in whom the caecum is not reached, and as a first line investigation in patients with severe respiratory disease.

In the early part of the study (on which much of the present data are based) double contrast barium enema combined with flexible sigmoidoscopy were used as the initial investigation and 26 carcinomas were thus detected. It seems probable that a further three carcinomas were not identified, however, resulting in a sensitivity of 89-7% for large bowel malignancy.

The prevalence of asymptomatic inflammatory bowel disease has been previously reported.\(^1\) Given the importance of surveillance of colitis this must be viewed as a positive aspect of the screening programme. In each of the eight subjects mentioned, there was macroscopic evidence of inflamed mucosa and it is therefore reasonable to assume that this was the cause of the positive faecal occult blood tests.

The extent to which the remainder of the gastrointestinal tract should be investigated in the remaining subjects in whom no satisfactory colorectal cause for bleeding has been found is controversial. In practical terms this would involve routine upper gastrointestinal endoscopy, possibly followed by a small bowel barium enema. Even then rare causes of blood loss, such as haemobilia, would be missed.

It may be argued that having identified an asymptomatic subject with a positive faecal occult blood test, one has an obligation to investigate fully the gastrointestinal tract if the colorectum is normal. However, Haemoccult and the more recently developed immunological tests have been shown to be relatively poor indicators of upper gastrointestinal abnormalities.\(^2\)\(^3\)\(^4\) This is probably a reflection of the degradation of blood that occurs during colonic transit. We have shown previously that Haemoccult is significantly less sensitive for caecal cancers than for cancers of the sigmoid or descending colons.\(^5\) If this is a reflection of gastrointestinal degradation, one would expect an even greater effect on blood from gastric or duodenal lesions.

An alternative strategy is to reserve upper gastrointestinal endoscopy for those patients with relevant symptoms. Whereas early colorectal neoplasia is generally an asymptomatic condition, there is evidence that gastric carcinoma produces dyspeptic symptoms in a significant proportion of subjects.\(^6\) In a programme for the early detection of gastric cancer, a yield of 3-4% for oesophageal and gastric cancer was obtained in subjects over the age of 40 years presenting to their general practitioners with dyspeptic symptoms.\(^7\) It is evident that this group of individuals should undergo investigation. Of the 14 subjects in the present study who underwent upper gastrointestinal endoscopy, five (35-7%) were shown to have benign gastrointestinal disease and one to have an early gastric carcinoma. It is therefore mandatory that upper gastrointestinal symptoms should be sought in Haemoccult positive subjects in whom large bowel investigations are normal.

Of the four patients with chronic dyspepsia, one who was not investigated was diagnosed as having a gastric cancer some 24 months after a negative large bowel examination. In retrospect, this symptomatic patient should have undergone gastroscopy after large bowel investigation and faecal occult blood test. This emphasises the importance of investigating those with upper gastrointestinal symptoms.

The remaining patients, who did not report upper gastrointestinal symptoms, have now been followed up for a median period of five years. The only gastrointestinal conditions which have been identified to date have been minor degrees of gastritis or oesophagitis in five patients, and it seems unlikely that there was an important gastrointestinal cause of blood loss at the time of the positive faecal occult blood test. In particular, we are reassured that no subjects in this group have presented with upper gastrointestinal malignancy and conclude that upper gastrointestinal investigations need not be performed routinely in screened subjects who have positive tests, but should be reserved for those with relevant symptoms.


